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Zika virus (ZIKV) is a flavivirus related to yellow fever, 
dengue, West Nile, and Japanese encephalitis viruses. In 
2007 ZIKV caused an outbreak of relatively mild disease 
characterized by rash, arthralgia, and conjunctivitis on Yap 
Island in the southwestern Pacific Ocean. This was the first 
time that ZIKV was detected outside of Africa and Asia. The 
history, transmission dynamics, virology, and clinical mani-
festations of ZIKV disease are discussed, along with the 
possibility  for  diagnostic  confusion  between  ZIKV  illness 
and dengue. The emergence of ZIKV outside of its previ-
ously known geographic range should prompt awareness of 
the potential for ZIKV to spread to other Pacific islands and 
the Americas.  
I
n April 2007, an outbreak of illness characterized by rash, 
arthralgia, and conjunctivitis was reported on Yap Island 
in the Federated States of Micronesia. Serum samples from 
patients in the acute phase of illness contained RNA of Zika 
virus (ZIKV), a flavivirus in the same family as yellow fe-
ver, dengue, West Nile, and Japanese encephalitis viruses. 
These findings show that ZIKV has spread outside its usual 
geographic range (1,2). 
Sixty years earlier, on April 18, 1947, fever developed 
in a rhesus monkey that had been placed in a cage on a 
tree platform in the Zika Forest of Uganda (3). The mon-
key, Rhesus 766, was a sentinel animal in the Rockefeller 
Foundation’s program for research on jungle yellow fever. 
Two days later, Rhesus 766, still febrile, was brought to 
the Foundation’s laboratory at Entebbe and its serum was 
inoculated into mice. After 10 days all mice that were in-
oculated intracerebrally were sick, and a filterable trans-
missible agent, later named Zika virus, was isolated from 
the mouse brains. In early 1948, ZIKV was also isolated 
from Aedes africanus mosquitoes trapped in the same for-
est (4). Serologic studies indicated that humans could also 
be infected (5). Transmission of ZIKV by artificially fed 
Ae. aegypti mosquitoes to mice and a monkey in a labora-
tory was reported in 1956 (6).
ZIKV was isolated from humans in Nigeria during 
studies conducted in 1968 and during 1971–1975; in 1 
study, 40% of the persons tested had neutralizing antibody 
to ZIKV (7–9). Human isolates were obtained from febrile 
children 10 months, 2 years (2 cases), and 3 years of age, 
all without other clinical details described, and from a 10 
year-old boy with fever, headache, and body pains (7,8). 
From 1951 through 1981, serologic evidence of human 
ZIKV infection was reported from other African coun-
tries such as Uganda, Tanzania, Egypt, Central African 
Republic, Sierra Leone (10), and Gabon, and in parts of 
Asia including India, Malaysia, the Philippines, Thailand, 
Vietnam, and Indonesia (10–14). In additional investiga-
tions, the virus was isolated from Ae. aegypti mosquitoes 
in Malaysia, a human in Senegal, and mosquitoes in Côte 
d’Ivoire (15–17). In 1981 Olson et al. reported 7 people 
with serologic evidence of ZIKV illness in Indonesia (11). 
A subsequent serologic study indicated that 9/71 (13%) 
human volunteers in Lombok, Indonesia, had neutralizing 
antibody to ZIKV (18). The outbreak on Yap Island in 
2007 shows that ZIKV illness has been detected outside of 
Africa and Asia (Figure 1).
Dynamics of Transmission
ZIKV has been isolated from Ae. africanus, Ae. api-
coargenteus, Ae. luteocephalus, Ae. aegypti, Ae vitattus, 
and Ae. furcifer mosquitoes (9,15,17,19). Ae. hensilii was 
the predominant mosquito species present on Yap during 
the ZIKV disease outbreak in 2007, but investigators were 
unable to detect ZIKV in any mosquitoes on the island dur-
ing the outbreak (2). Dick noted that Ae. africanus mosqui-
toes, which were abundant and infected with ZIKV in the 
Zika Forest, were not likely to enter monkey cages such as 
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the one containing Rhesus 766 (5) raising the doubt that 
the monkey might have acquired ZIKV from some other 
mosquito species or through some other mechanism. Dur-
ing the studies of yellow fever in the Zika Forest, investiga-
tors had to begin tethering monkeys in trees because caged 
monkeys did not acquire yellow fever virus when the virus 
was present in mosquitoes (5). Thus, despite finding ZIKV 
in Ae. Africanus mosquitoes, Dick was not sure whether or 
not these mosquitoes were actually the vector for enzootic 
ZIKV transmission to monkeys.
Boorman and Porterfield subsequently demonstrated 
transmission of ZIKV to mice and monkeys by Ae. aegypti 
in a laboratory (6). Virus content in the mosquitoes was 
high on the day of artificial feeding, dropped to undetect-
able levels through day 10 after feeding, had increased by 
day 15, and remained high from days 20 through 60 (6). 
Their study suggests that the extrinsic incubation period for 
ZIKV in mosquitoes is ≈10 days. The authors cautioned 
that their results did not conclusively demonstrate that Ae. 
aegypti mosquitoes could transmit ZIKV at lower levels 
of viremia than what might occur among host animals in 
natural settings. Nevertheless, their results, along with the 
viral isolations from wild mosquitoes and monkeys and the 
phylogenetic proximity of ZIKV to other mosquito-borne 
flaviviruses, make it reasonable to conclude that ZIKV is 
transmitted through mosquito bites.
There is to date no solid evidence of nonprimate res-
ervoirs of ZIKV, but 1 study did find antibody to ZIKV in 
rodents (20). Further laboratory, field, and epidemiologic 
studies would be useful to better define vector competence 
for ZIKV, to determine if there are any other arthropod 
vectors or reservoir hosts, and to evaluate the possibil-
ity of congenital infection or transmission through blood 
transfusion.
Virology and Pathogenesis
ZIKV is an RNA virus containing 10,794 nucleotides 
encoding 3,419 amino acids. It is closely related to Spond-
weni virus; the 2 viruses are the only members of their clade 
within the mosquito-borne cluster of flaviviruses (Figure 2) 
(1,21,22). The next nearest relatives include Ilheus, Rocio, 
and St. Louis encephalitis viruses; yellow fever virus is the 
prototype of the family, which also includes dengue, Japa-
nese encephalitis, and West Nile viruses (1,21). Studies in 
the Zika Forest suggested that ZIKV infection blunted the 
viremia caused by yellow fever virus in monkeys but did 
not block transmission of yellow fever virus (19,23).
Information regarding pathogenesis of ZIKV is scarce 
but  mosquito-borne  flaviviruses  are  thought  to  replicate 
initially in dendritic cells near the site of inoculation then 
spread to lymph nodes and the bloodstream (24). Although 
flaviviral replication is thought to occur in cellular cyto-
plasm,  1  study  suggested  that  ZIKV  antigens  could  be 
found in infected cell nuclei (25). To date, infectious ZIKV 
has been detected in human blood as early as the day of 
illness onset; viral nucleic acid has been detected as late as 
11 days after onset (1,26). The virus was isolated from the 
serum of a monkey 9 days after experimental inoculation 
(5). ZIKV is killed by potassium permanganate, ether, and 
temperatures >60°C, but it is not effectively neutralized 
with 10% ethanol (5).
Clinical Manifestations
The first well-documented report of human ZIKV dis-
ease was in 1964 when Simpson described his own occu-
pationally acquired ZIKV illness at age 28 (27). It began 
with mild headache. The next day, a maculopapular rash 
covered his face, neck, trunk, and upper arms, and spread 
to his palms and soles. Transient fever, malaise, and back 
pain developed. By the evening of the second day of illness 
he was afebrile, the rash was fading, and he felt better. By 
day three, he felt well and had only the rash, which disap-
peared over the next 2 days. ZIKV was isolated from serum 
collected while he was febrile. 
In  1973,  Filipe  et  al.  reported  laboratory-acquired 
ZIKV illness in a man with acute onset of fever, headache, 
and joint pain but no rash (26). ZIKV was isolated from 
serum collected on the first day of symptoms; the man’s 
illness resolved in ≈1 week.
Of the 7 ZIKV case-patients in Indonesia described 
by Olson et al. all had fever, but they were detected by 
hospital-based surveillance for febrile illness (11). Other 
manifestations  included  anorexia,  diarrhea,  constipation, 
abdominal pain, and dizziness. One patient had conjunc-
tivitis but none had rash. The outbreak on Yap Island was 
characterized by rash, conjunctivitis, and arthralgia (1,2). 
Other less frequent manifestations included myalgia, head-
ache, retroorbital pain, edema, and vomiting (2).






Figure 1. Approximate known distribution of Zika Virus, 1947–2007. 
Figure  1.  Approximate  known  distribution  of  Zika  virus,  1947–
2007. Red circle represents Yap Island. Yellow indicates human 
serologic evidence; red indicates virus isolated from humans; green 
represents mosquito isolates.Zika Virus Outside Africa
Diagnosis
Diagnostic tests for ZIKV infection include PCR tests 
on acute-phase serum samples, which detect viral RNA, 
and other tests to detect specific antibody against ZIKV in 
serum. An ELISA has been developed at the Arboviral Di-
agnostic and Reference Laboratory of the Centers for Dis-
ease Control and Prevention (Atlanta, GA, USA) to detect 
immunoglobulin (Ig) M to ZIKV (1). In the samples from 
Yap Island, cross-reactive results in sera from convales-
cent-phase patients occurred more frequently among pa-
tients with evidence of previous flavivirus infections than 
among those with apparent primary ZIKV infections (1,2). 
Cross-reactivity was more frequently noted with dengue vi-
rus than with yellow fever, Japanese encephalitis, Murray 
Valley encephalitis, or West Nile viruses, but there were 
too few samples tested to derive robust estimates of the 
sensitivity and specificity of the ELISA. IgM was detect-
able as early as 3 days after onset of illness in some per-
sons; 1 person with evidence of previous flavivirus infec-
tion had not developed IgM at day 5 but did have it by day 
8 (1). Neutralizing antibody developed as early as 5 days 
after illness onset. The plaque reduction neutralization as-
say generally has improved specificity over immunoassays, 
but may still yield cross-reactive results in secondary fla-
vivirus infections. PCR tests can be conducted on samples 
obtained less than 10 days after illness onset; 1 patient from 
Yap Island still had detectable viral RNA on day 11 (1). In 
general, diagnostic testing for flavivirus infections should 
include an acute-phase serum sample collected as early as 
possible after onset of illness and a second sample collected 
2 to 3 weeks after the first.
Public Health Implications
Because the virus has spread outside Africa and Asia, 
ZIKV should be considered an emerging pathogen. Fortu-
nately, ZIKV illness to date has been mild and self-limited, 
but before West Nile virus caused large outbreaks of neuro-
invasive disease in Romania and in North America, it was 
also considered to be a relatively innocuous pathogen (28). 
The discovery of ZIKV on the physically isolated commu-
nity of Yap Island is testimony to the potential for travel 
or commerce to spread the virus across large distances. A 
medical volunteer who was on Yap Island during the ZIKV 
disease outbreak became ill and was likely viremic with 
ZIKV after her return to the United States (2). The com-
petence of mosquitoes in the Americas for ZIKV is not 
known and this question should be addressed. Spread of 
ZIKV across the Pacific could be difficult to detect because 
of the cross-reactivity of diagnostic flavivirus antibody as-
says. ZIKV disease could easily be confused with dengue 
and might contribute to illness during dengue outbreaks. 
Recognition of the spread of ZIKV and of the impact of 
ZIKV on human health will require collaboration between 
clinicians, public health officials, and high-quality refer-
ence laboratories.
Given that the epidemiology of ZIKV transmission on 
Yap Island appeared to be similar to that of dengue, strat-
egies for prevention and control of ZIKV disease should 
include promoting the use of insect repellent and interven-
tions to reduce the abundance of potential mosquito vec-
tors. Officials responsible for public health surveillance in 
the Pacific region and the United States should be alert to 
the potential spread of ZIKV and keep in mind the possible 
diagnostic confusion between ZIKV illness and dengue.
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Figure 2. Phylogenetic relationship of Zika virus to other flaviviruses 
based on nucleic acid sequence of nonstructural viral protein 5, 
with permission from Dr Robert Lanciotti (1). Enc, encephalitis; ME, 
meningoencephalitis.SYNOPSIS
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